Viridian Therapeutics, Inc./DE Expense Breakdown
No Expense Breakdown for VRDN on this site yet.
- 2026-06-30: Reportable $126.44M.
- 2025-06-30: Reportable $106.73M.
Source checked: the stored Expense Breakdown page for VRDN.
Expenses by product
Operating expenses: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $126.44M |
| 2025-06-30 | $106.73M |
Research And Development Expense Excluding Share Based Compensation Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $64.19M |
| 2025-06-30 | $81.40M |
Share-based Payment Arrangement, Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $16.98M |
| 2025-06-30 | $10.84M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |